What Is PNC-27? Uses, Benefits, Safety, FDA Status, and Evidence
Medical review note: This article is for educational purposes only and does not provide medical advice. PNC-27 is not FDA-approved for cancer, tumors, leukemia, immune support, anti-aging, prevention, or any therapeutic use. Products sold online as PNC-27, PNC27, p53 peptide, cancer peptide, MDM2 peptide, HDM-2 peptide, or “research use only” PNC-27 may carry serious safety, quality, legal, and regulatory risks.
Quick answer
PNC-27 is an experimental anticancer peptide derived from the p53 tumor-suppressor protein. It is typically described as a 32-residue chimeric peptide containing an HDM-2/MDM2-binding p53-derived sequence attached to a cell-penetrating peptide sequence. In laboratory studies, PNC-27 binds membrane-expressed HDM-2 on cancer cells and forms transmembrane pores that can rapidly kill cancer cells through membrane lysis or necrosis. However, PNC-27 is not FDA-approved, has no strong published human clinical evidence proving cancer-treatment benefit, and has been associated with FDA warning/enforcement context and serious safety concerns. Online claims that PNC-27 cures cancer should be treated as dangerous and unsupported.
Key facts about PNC-27
| Question | Answer |
|---|---|
| What is PNC-27? | An experimental p53-derived anticancer peptide studied for selective cancer-cell membrane lysis. |
| Other names | PNC27, PNC-27 anticancer peptide, p53-HDM2 peptide, p53-derived peptide, MDM2-binding peptide. |
| Related peptide | PNC-28 is a related p53-derived anticancer peptide studied in similar cancer-cell research. |
| Peptide class | Experimental anticancer peptide / p53-derived chimeric peptide / membrane-active peptide. |
| Main mechanism | Binds membrane-expressed HDM-2/MDM2 on cancer cells and forms cytotoxic transmembrane pores, causing rapid membrane lysis or necrosis in experimental systems. |
| FDA-approved? | No. PNC-27 is not FDA-approved. |
| Main studied uses | Cancer-cell killing, solid tumor cell lines, hematologic cancer cell lines, HDM-2/MDM2 membrane targeting, peptide-induced pore formation, and experimental oncology research. |
| Human evidence level | Very limited. Strong published human clinical outcome evidence is lacking. |
| Animal/lab evidence level | Moderate preclinical evidence for selective cancer-cell killing in cell and animal research models. |
| Common online claims | “Cancer peptide,” “p53 cancer cure,” “MDM2 cancer peptide,” “tumor-killing peptide,” “alternative cancer treatment,” “non-toxic cancer cure.” |
| Sports status | Not found here as specifically named on the WADA prohibited list. Because PNC-27 is not approved for human therapeutic use, athletes should verify status through WADA, USADA, or Global DRO and avoid unapproved research-use products. |
| Main safety concern | No FDA approval, lack of robust human clinical data, cancer-treatment delay risk, product contamination or mislabeling, serious adverse-event concerns, and unsafe online cancer-cure marketing. |
What is PNC-27?
PNC-27 is an experimental anticancer peptide based on part of the p53 tumor-suppressor protein.
PNC-27 is usually described as a chimeric peptide containing:
- A p53-derived sequence that binds HDM-2/MDM2
- A cell-penetrating peptide sequence derived from antennapedia/penetratin-like transport biology
HDM-2, also called MDM2 in human literature, is best known as a protein that regulates p53. In PNC-27 research, the key idea is different: many cancer cells express HDM-2 on their membranes, while normal cells generally do not express it in the same way. PNC-27 is proposed to bind that membrane HDM-2 and form pores that kill the cancer cell.
A PubMed study describes PNC-27 as a 32-residue peptide containing an HDM-2 binding domain and a cell-penetrating peptide leader sequence that kills cancer cells but not normal cells in experimental systems.
A PMC study reported that PNC-27 adopts an HDM-2-binding conformation and targets HDM-2 in cancer-cell membranes, allowing it to induce membranolysis selectively.
The key distinction:
PNC-27 is a real experimental anticancer peptide, but it is not an approved cancer drug and should not be treated as a proven cancer cure.
How does PNC-27 work?
PNC-27’s proposed mechanism is unusual.
Most cancer drugs work by blocking signaling pathways, damaging DNA, activating the immune system, inhibiting cell division, or targeting specific mutations.
PNC-27 is proposed to work by direct membrane attack.
Research describes this sequence of events:
- PNC-27 reaches the cancer-cell membrane.
- It binds HDM-2/MDM2 expressed on the cancer-cell membrane.
- PNC-27 and HDM-2/MDM2 co-localize.
- Transmembrane pores form.
- The cancer cell undergoes rapid membrane lysis or necrosis.
A 2024 PubMed review describes PNC-27 as killing cancer cells by co-localizing with membrane-expressed HDM-2, resulting in transmembrane pore formation. A related PMC review describes this mechanism as peptide-induced pore formation, also called “poptosis.”
In plain English:
PNC-27 is designed to punch lethal holes in cancer-cell membranes by targeting a protein found on those cancer-cell membranes.
That mechanism is interesting, but it does not prove human clinical benefit.
A peptide killing cancer cells in dishes or animal models does not prove that it cures cancer in humans, is safe, works across tumor types, reaches tumors adequately, avoids immune reactions, avoids contamination risk, or can replace standard oncology care.
What is PNC-27 used for?
PNC-27 is not approved for any use. It is an experimental compound.
| Use | Evidence level | What is known | What is not known | |---|---|---| | Cancer-cell killing | Preclinical evidence | PNC-27 kills multiple cancer-cell types in lab studies through membrane HDM-2 targeting and pore formation. | Human clinical efficacy is not established. | | Solid tumors | Preclinical evidence | Studies report effects in cancer cell lines such as pancreatic, breast, ovarian, lung, colon, and cervical cancer models. | No FDA-approved solid tumor indication exists. | | Hematologic cancers | Preclinical evidence | Some studies describe effects in leukemia-related cancer-cell models. | Human leukemia treatment benefit is not established. | | Combination with chemotherapy | Preclinical evidence | One study reported synergy between PNC-27 and paclitaxel in ovarian cancer models. | Human combination-treatment safety and efficacy are not established. | | Alternative cancer therapy | Unsupported and dangerous | Online marketing may claim broad cancer benefit. | PNC-27 is not an approved cancer therapy and may delay proven treatment. | | Cancer prevention | Unsupported | No credible clinical evidence supports preventive use. | It is not a prevention drug. | | Anti-aging / wellness | Unsupported | No credible evidence supports wellness use. | It is not an anti-aging peptide. | | Online research-use PNC-27 | High risk | Sold by some peptide vendors or alternative cancer sources. | Identity, purity, sterility, contamination, dose, safety, and legality may be unknown. |
What does the research show?
Preclinical cancer-cell evidence
PNC-27 has meaningful preclinical research.
A 2010 PubMed study reported that PNC-27 adopts an HDM-2-binding conformation and kills cancer cells by binding HDM-2 in their membranes.
A 2010 PubMed study reported that PNC-27 induces tumor-cell membrane lysis as the intact peptide rather than through peptide fragments.
A 2014 PubMed study described PNC-27 as a membrane-active peptide that binds HDM-2 expressed in cancer-cell membranes.
The practical interpretation:
PNC-27 has real lab-based anticancer activity, but lab activity is not clinical proof.
2024 review evidence
PNC-27 continues to be studied and reviewed.
A 2024 PubMed review states that PNC-27 kills cancer cells through co-localization with membrane-expressed HDM-2 and transmembrane pore formation.
A 2024 PMC review describes the broader concept of peptide-induced transmembrane pore formation and discusses PNC-27 and PNC-28.
The practical interpretation:
PNC-27 remains scientifically interesting, but the literature still centers heavily on mechanism and preclinical evidence, not approval-level human outcomes.
Ex vivo and combination evidence
PNC-27 has been studied in ex vivo and combination contexts.
A PubMed ex vivo ovarian cancer study evaluated PNC-27 in patient-derived ovarian cancer research context.
A PubMed study on paclitaxel synergy reported synergy between PNC-27 and paclitaxel in ovarian cancer models.
The practical interpretation:
These studies support further research, not consumer use or cancer-treatment claims.
FDA and enforcement context
PNC-27 is not FDA-approved.
A Federal Register public-inspection document states that FDA had not approved PNC-27 for use in the United States as a drug to treat any disease, including any form of cancer.
A 2017 American Journal of Gastroenterology case report on experimental PNC-27 therapy and massive GI hemorrhage stated that PNC-27 was not approved for use in the U.S. and was being marketed online as a non-toxic potential cure for various cancers.
Reports summarizing FDA warnings also stated that PNC-27 was marketed with cancer-cure claims despite lacking FDA approval, and that FDA cautioned patients against use.
The practical interpretation:
The FDA status is not ambiguous: PNC-27 is not an approved cancer treatment.
Human clinical evidence
This is the critical weakness.
PNC-27 has mechanistic, cell-line, animal, ex vivo, and review literature. But strong, peer-reviewed, controlled human clinical trial evidence showing that PNC-27 safely treats cancer is not established.
The practical interpretation:
A person with cancer should not replace evidence-based oncology care with PNC-27. That would be medically reckless.
Evidence summary
| Claim | Evidence verdict | Explanation |
|---|---|---|
| “PNC-27 is p53-derived.” | Supported | PNC-27 contains a p53-derived HDM-2/MDM2 binding sequence. |
| “PNC-27 targets membrane HDM-2/MDM2.” | Supported preclinically | Studies report binding to HDM-2 on cancer-cell membranes. |
| “PNC-27 forms pores in cancer-cell membranes.” | Supported preclinically | Reviews and studies describe transmembrane pore formation and cell lysis. |
| “PNC-27 kills cancer cells in lab studies.” | Supported preclinically | Multiple cancer-cell studies show cytotoxicity. |
| “PNC-27 cures cancer in humans.” | Not established | Strong human clinical outcome evidence is lacking. |
| “PNC-27 is FDA-approved.” | False | FDA has not approved PNC-27 for any disease, including cancer. |
| “PNC-27 is non-toxic.” | Not established | Human safety data are inadequate, and case/enforcement context raises concern. |
| “PNC-27 can replace chemotherapy, surgery, radiation, immunotherapy, or targeted therapy.” | False and dangerous | No evidence supports replacing standard oncology care. |
| “Research-use PNC-27 is clinically proven.” | False | Research-use products are not FDA-approved consumer therapeutic products. |
| “Online PNC-27 cancer products are reliable.” | Not established | Quality, sterility, identity, contamination, and dosing may be unknown. |
Is PNC-27 FDA-approved?
No. PNC-27 is not FDA-approved.
There is no FDA-approved PNC-27 product for:
- Cancer
- Tumors
- Leukemia
- Ovarian cancer
- Pancreatic cancer
- Breast cancer
- Lung cancer
- Colon cancer
- Cervical cancer
- Prostate cancer
- Cancer prevention
- Immune support
- Anti-aging
- General wellness
- Any human therapeutic use
The key distinction:
PNC-27 has experimental anticancer research, but it is not an approved cancer medication.
Is PNC-27 legal?
PNC-27’s legal status depends on jurisdiction, product type, intended use, route, manufacturing, and whether it is part of authorized research.
For U.S. readers:
PNC-27 is not an FDA-approved drug, and online availability does not mean it is legally marketed for human cancer treatment.
Some sellers market PNC-27 as a cancer peptide, p53 therapy, MDM2 peptide, alternative cancer cure, or research-use peptide. That does not make it safe, approved, legal, or appropriate for consumer use.
The blunt version:
Buying “research use only” PNC-27 online is not the same as receiving an FDA-approved oncology treatment from a legitimate medical provider.
Is PNC-27 banned in sports?
I did not find PNC-27 specifically named on the WADA prohibited list in the sources reviewed here.
However, PNC-27 is not approved for human therapeutic use. WADA’s prohibited framework includes non-approved pharmacological substances under S0. Athletes should verify PNC-27 through official anti-doping resources before use.
The WADA Prohibited List and USADA prohibited-list guidance should be checked directly.
The practical advice:
Athletes should avoid PNC-27 unless they have formal anti-doping clearance. An unapproved experimental anticancer peptide is not a safe anti-doping choice.
Safety and side effects
PNC-27 should be treated as high risk.
Possible or reported concerns include:
- Unknown human safety profile
- Unknown tumor-specific dosing and exposure
- Unknown off-target effects
- Immune or allergic reactions
- Infusion or injection reactions
- Contamination risk
- Sterility risk
- Endotoxin risk
- Product mislabeling
- Incorrect concentration
- Delayed or abandoned standard cancer care
- Serious adverse-event risk in medically fragile cancer patients
- Unknown interaction risk with chemotherapy, immunotherapy, radiation, surgery, anticoagulants, steroids, targeted therapy, or experimental cancer drugs
The biggest risk is not only direct toxicity.
The biggest practical risk is that a patient delays or replaces evidence-based cancer treatment with an unapproved online peptide marketed as a cure.
That can kill people.
PNC-27 vs similar cancer peptides and therapies
| Compound | Category | Main difference |
|---|---|---|
| PNC-27 | Experimental p53-derived anticancer peptide | Targets membrane HDM-2/MDM2 and forms cytotoxic pores in preclinical models. |
| PNC-28 | Related p53-derived anticancer peptide | Similar research family, also studied for cancer-cell membrane lysis. |
| p53 gene therapy | Gene-based cancer approach | Attempts to restore or deliver p53 function, not the same as PNC-27 pore formation. |
| MDM2 inhibitors | Small-molecule oncology drugs | Often aim to restore p53 signaling by inhibiting MDM2-p53 interaction, different mechanism. |
| Chemotherapy | Approved cancer drug class | Established clinical evidence and regulated use for specific cancers. |
| Immunotherapy | Approved cancer drug class | Uses immune-system mechanisms, not direct peptide pore formation. |
| Targeted therapy | Approved molecular cancer therapy | Targets specific mutations or pathways, different from PNC-27. |
| Radiation therapy | Standard cancer treatment | Local tumor control through radiation-induced DNA damage. |
| Cancer vaccines | Immunotherapeutic strategy | Stimulate immune recognition, not direct membrane pore formation. |
The key distinction:
PNC-27 belongs in the experimental anticancer peptide category. It is not an approved oncology drug, not chemotherapy, not immunotherapy, and not a substitute for standard care.
Why is PNC-27 sold as “research use only”?
Some online sellers use “research use only” language to sell PNC-27 outside normal drug channels.
That label is not a trust signal.
A serious reader should understand this distinction:
| Product type | What it means |
|---|---|
| Laboratory PNC-27 | Experimental compound used in controlled research settings. |
| Clinical-trial PNC-27 | No strong approval-level clinical program established here. |
| FDA-approved PNC-27 | Does not exist. |
| Research-use PNC-27 | Not an FDA-approved consumer therapeutic product. |
| Online PNC-27 cancer product | High risk for identity, purity, sterility, concentration, contamination, and false medical claims. |
| “Cancer cure” PNC-27 | Dangerous marketing claim, not established medical evidence. |
How to evaluate PNC-27 claims online
| Claim | What to verify |
|---|---|
| “FDA-approved PNC-27” | False. PNC-27 is not FDA-approved. |
| “Clinically proven cancer cure” | False. Strong human clinical outcome evidence is lacking. |
| “Kills all cancers” | Unsupported. Lab cytotoxicity does not prove broad human cancer cure. |
| “Non-toxic cancer therapy” | Not established. Human safety data are inadequate. |
| “Works better than chemo” | Unsupported and dangerous unless proven in controlled trials. |
| “No need for oncology treatment” | Dangerous. This can delay evidence-based care. |
| “Targets only cancer cells” | Preclinical claim. Human safety and selectivity are not established. |
| “Research use only” | This does not mean safe, legal, approved, or appropriate for human use. |
| “Safe because it is p53-derived” | False. Origin from a biological sequence does not prove drug safety. |
| “Third-party tested” | Ask for batch-specific identity, purity, LC-MS, HPLC, sterility, endotoxin, microbial, and stability data. |
| “Used successfully outside the U.S.” | Demand peer-reviewed controlled human clinical evidence, not anecdotes. |
Bottom line
PNC-27 is an experimental p53-derived anticancer peptide that targets membrane HDM-2/MDM2 and can kill cancer cells in preclinical studies through transmembrane pore formation. The biology is interesting and scientifically legitimate as a research area.
The most defensible conclusion is:
PNC-27 is a preclinical/experimental anticancer peptide, not a proven human cancer therapy. It is not FDA-approved, strong human clinical outcome evidence is lacking, FDA-related materials have warned against unapproved cancer-treatment claims, and online PNC-27 products should not be treated as legitimate cancer medicines.
FAQ
What is PNC-27?
PNC-27 is an experimental p53-derived anticancer peptide studied for selective cancer-cell killing through membrane HDM-2/MDM2 binding and pore formation.
What does PNC-27 do?
In preclinical studies, PNC-27 binds HDM-2/MDM2 expressed on cancer-cell membranes and forms transmembrane pores that can cause rapid cancer-cell lysis or necrosis.
Is PNC-27 FDA-approved?
No. PNC-27 is not FDA-approved for cancer, tumors, leukemia, cancer prevention, immune support, anti-aging, or any other therapeutic use.
Does PNC-27 cure cancer?
No reliable human clinical evidence establishes PNC-27 as a cancer cure. Cancer-cure claims are unsupported and dangerous.
Is PNC-27 chemotherapy?
No. PNC-27 is an experimental anticancer peptide, not chemotherapy. It has a different proposed mechanism involving membrane pore formation.
Is PNC-27 the same as PNC-28?
No. PNC-27 and PNC-28 are related p53-derived anticancer peptides, but they are distinct compounds.
What is HDM-2 or MDM2?
HDM-2, also called MDM2, is a protein best known for regulating p53. In PNC-27 research, membrane-expressed HDM-2/MDM2 on cancer cells is proposed as a target for pore formation.
Does PNC-27 kill cancer cells?
PNC-27 kills multiple cancer-cell types in laboratory and preclinical studies. That does not prove it safely or effectively treats cancer in humans.
Is PNC-27 safe?
There is not enough human safety evidence to call PNC-27 safe. Concerns include unknown toxicity, immune reactions, contamination risk, mislabeling, unknown interactions with cancer therapies, and the risk of delaying proven treatment.
Is PNC-27 legal?
PNC-27 is not an FDA-approved drug. Online sale as a research peptide does not mean it is legally marketed for human cancer treatment.
Is PNC-27 banned in sports?
I did not find PNC-27 specifically named on the WADA prohibited list in the sources reviewed here. Because it is not approved for human therapeutic use, athletes should verify status with WADA, USADA, or Global DRO and avoid unapproved research-use products.
Why do sellers call PNC-27 “research use only”?
Sellers often use “research use only” language because PNC-27 is not FDA-approved for consumer therapeutic use. The phrase does not make the product safe, legal, approved, or clinically proven.
What is the biggest risk with PNC-27?
The biggest risks are using an unapproved experimental cancer peptide without human clinical proof, relying on cancer-cure claims, buying contaminated or mislabeled products, and delaying evidence-based oncology care.
Sources
- PubMed: Anti-Cancer Peptide PNC-27 Kills Cancer Cells by Unique Mechanism
- PMC: Poptosis or Peptide-Induced Transmembrane Pore Formation
- PubMed: PNC-27, a Chimeric p53-Penetratin Peptide Binds to HDM-2
- PubMed: Anticancer peptide PNC-27 adopts an HDM-2-binding conformation
- PMC: Anticancer peptide PNC-27 adopts an HDM-2-binding conformation
- PubMed: The Anti-Cancer Peptide, PNC-27, Induces Tumor Cell Lysis
- PubMed: The anti-cancer peptide, PNC-27, induces tumor cell lysis as the intact peptide
- PubMed: Targeting Membrane HDM-2 by PNC-27 Induces Necrosis
- PubMed: Ex vivo Efficacy of Anti-Cancer Drug PNC-27 in Ovarian Cancer
- PubMed: Synergy between Paclitaxel and Anti-Cancer Peptide PNC-27
- PubMed: PNC-28, a p53-derived peptide that is cytotoxic to cancer cells
- PubMed: The penetratin sequence in the anticancer PNC-28 peptide
- Federal Register Public Inspection: FDA Has Not Approved PNC-27 for Cancer Treatment
- American Journal of Gastroenterology: Experimental PNC-27 Therapy and Massive GI Hemorrhage
- Pharmacy Times: FDA Avoid PNC-27, Discuss Approved Treatment Options
- Oncology Nursing News: FDA Cautions Against PNC-27 Use
- WADA: Prohibited List
- WADA: 2026 Prohibited List PDF
- USADA: WADA Prohibited List Guidance
Frequently asked questions
What is PNC-27?
PNC-27 is an experimental p53-derived anticancer peptide studied for selective cancer-cell killing through membrane HDM-2/MDM2 binding and pore formation.
What does PNC-27 do?
In preclinical studies, PNC-27 binds HDM-2/MDM2 expressed on cancer-cell membranes and forms transmembrane pores that can cause rapid cancer-cell lysis or necrosis.
Is PNC-27 FDA-approved?
No. PNC-27 is not FDA-approved for cancer, tumors, leukemia, cancer prevention, immune support, anti-aging, or any other therapeutic use.
Does PNC-27 cure cancer?
No reliable human clinical evidence establishes PNC-27 as a cancer cure. Cancer-cure claims are unsupported and dangerous.
Is PNC-27 chemotherapy?
No. PNC-27 is an experimental anticancer peptide, not chemotherapy. It has a different proposed mechanism involving membrane pore formation.
Is PNC-27 the same as PNC-28?
No. PNC-27 and PNC-28 are related p53-derived anticancer peptides, but they are distinct compounds.
What is HDM-2 or MDM2?
HDM-2, also called MDM2, is a protein best known for regulating p53. In PNC-27 research, membrane-expressed HDM-2/MDM2 on cancer cells is proposed as a target for pore formation.
Does PNC-27 kill cancer cells?
PNC-27 kills multiple cancer-cell types in laboratory and preclinical studies. That does not prove it safely or effectively treats cancer in humans.
Is PNC-27 safe?
There is not enough human safety evidence to call PNC-27 safe. Concerns include unknown toxicity, immune reactions, contamination risk, mislabeling, unknown interactions with cancer therapies, and the risk of delaying proven treatment.
Is PNC-27 banned in sports?
No official WADA source was found here specifically naming PNC-27 as prohibited. Because it is not approved for human therapeutic use, athletes should verify status with WADA, USADA, or Global DRO and avoid unapproved research-use products.
Sources
- [1]
- [2]
- [3]
- [4]
- [5]
- [6]
- [7]
- [8]
- [9]
- [10]
- [11]PubMed: PNC-28, a p53-derived peptide that is cytotoxic to cancer cells
Related Preclinical
- [12]PubMed: The penetratin sequence in the anticancer PNC-28 peptide
Related Preclinical
- [13]
- [14]
- [15]
- [16]Oncology Nursing News: FDA Cautions Against PNC-27 Use
Regulatory News
- [17]WADA: Prohibited List
Anti Doping
- [18]WADA: 2026 Prohibited List PDF
Anti Doping
- [19]USADA: WADA Prohibited List Guidance
Anti Doping
Last updated May 9, 2026